Core Viewpoint - The article highlights the increasing prevalence of obesity in China, emphasizing the need for effective weight management strategies in response to the "Healthy China 2030" initiative [1][4]. Summary by Sections Obesity Prevalence - A recent study reveals that among 15.8 million adult participants, 34.8% are overweight (BMI 24-28 kg/m²) and 14.1% are obese (BMI ≥28 kg/m²) [5]. Age and Gender Differences - Obesity rates show significant gender differences, with 41.1% of men being overweight compared to 27.7% of women, and 18.2% of men being obese versus 9.4% of women [6]. - The peak age for overweight men is between 50-54 years, while for women it is 65-69 years. The highest obesity rates for men occur at 35-39 years, while for women it peaks at 70-74 years [6]. Geographic Disparities - Individuals in northern China are more prone to obesity than those in the south, with Inner Mongolia, Shandong, and Hebei showing the highest rates of overweight and obesity [8]. Comorbidities Associated with Obesity - Nearly 90% of obese individuals have comorbidities, with the most common being fatty liver (34.9%), prediabetes (27.6%), dyslipidemia (24.9%), and hypertension (17.6%) [9]. - The likelihood of having comorbidities increases with higher BMI, indicating a direct correlation between weight and health issues [10]. Trends in Younger Populations - The report indicates a rising trend in overweight and obesity rates among younger populations, stressing the importance of self-discipline in maintaining a healthy lifestyle [11]. Effective Weight Management Strategies - Recommendations for effective weight management include maintaining a balanced diet, engaging in regular physical activity, monitoring weight regularly, managing hunger, and adopting a gradual approach to weight loss [12][15][18][20][21]. - The World Health Organization suggests a weight loss target of 0.5-1 kg per week to ensure health and sustainability [22].

整理 | GLP1减重宝典内容团队 近日，瑞德林生物合成的司美格鲁肽侧链成功通过美国食品药品监督管理局（FDA）药品主文件（Drug Master File, DMF）备案。这 是继其司美格鲁肽原料药及主链完成备案后，瑞德林在多肽生物医药领域达成的又一重要里程碑，充分证明了公司在司美格鲁肽全产业 链上的技术实力与合规能力，标志着瑞德林在全球医药领域的持续进步与重要突破。 美国食品药品监督管理局（FDA）药物主文件（Drug Master File）备案，是制药行业中用于提交有关药物成分、生产工艺、质量控制 等信息的正式文件，旨在全面展示产品的制造流程、原材料选用、化学特性分析、质量控制手段及稳定性数据等关键环节，确保药品符 合FDA的严格标准，为药品的质量、安全性和有效性奠定坚实基础。 版权声明：所有「GLP1减重宝典」的原创文章，转载须联系授权，并在文首/文末注明来源、作者、微信ID，否则减重宝典将向其追究法律责 任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题，敬请原作者联系我们。合作事宜，请添加微信：andyxu365 加入专家库与我们深度讨论 「GLP-1俱乐部」覆盖数百位专业人士， ...

Core Viewpoint - The article discusses the gastrointestinal discomfort associated with GLP-1 agonists like Semaglutide and Tirzepatide, highlighting the importance of dietary adjustments and lifestyle changes to alleviate these symptoms [2][17]. Dietary Recommendations - **Eating Pace**: It is recommended to slow down eating and consume smaller portions 5-6 times a day to reduce stomach burden [5]. - **High Protein and Fiber**: Incorporating protein sources such as chicken, fish, tofu, and low-fat yogurt, along with dietary fibers from beans, whole grains, vegetables, and fruits, can help maintain muscle and promote digestive health [6]. - **Avoiding High-Fat and High-Sugar Foods**: It is advised to steer clear of fried foods, fatty meats, pastries, ice cream, and sugary drinks, as well as spicy and acidic foods to manage stomach acid and discomfort [7]. - **Gentle and Easily Digestible Foods**: Foods like porridge, steamed eggs, soft noodles, bananas, and baked sweet potatoes are recommended to ease nausea [9]. - **Hydration and Probiotics**: Drinking 1.5-2 liters of water daily, along with probiotics from yogurt or pickles, can help maintain gut flora balance [10]. Expert Insights - Recommendations from foreign experts include consuming non-starchy vegetables, fruits, whole grains, and lean proteins while avoiding high-fat snacks and desserts [14]. - High-fiber, low-GI foods combined with protein can alleviate bloating and reduce heartburn frequency [14]. Lifestyle Adjustments - **Regular Exercise**: Engaging in 30 minutes of daily activities like brisk walking or swimming can promote gastrointestinal motility [15]. - **Routine Eating and Mindful Eating**: Establishing fixed meal times and practicing mindful eating can enhance digestion [15]. - **Stress Management**: Techniques such as meditation and yoga can help reduce anxiety that may interfere with the digestive system [15]. - **Supplementation**: Under medical advice, short-term use of fiber, probiotics, and magnesium may be beneficial [15]. Summary - A combination of high protein, high fiber, low-fat, and low-sugar diets, along with small, frequent meals and gentle lifestyle practices, is the most effective approach to alleviate gastrointestinal discomfort during the use of Semaglutide or Tirzepatide [17][18].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 近日，《柳叶刀》发布了全球疾病负担研究2021（GBD 2021）的最新成果，系统梳理了1990-2021年全球及各地区25岁及以上成年人超重和肥 胖的现状，并对2050年进行了预测。数据显示，2021年全球近一半成年人受到超重或肥胖困扰，其中中国超重/肥胖人数高达4.02亿，位居世界 第一。1990年至2021年，女性肥胖率上升104.9%，男性肥胖率更是飙升155.1%。预计到2050年，全球25岁及以上的超重和肥胖人数将增至38 亿，其中肥胖患者将达到19.5亿。中国依然"领跑"全球，预计将有6.27亿人超重或肥胖。 "有些同志腰围有点大，体重也超标了，甚至有人已经患上慢性病。""像你这样的大肚子，就是我们重点关注的对象。" ▍30年"胖"潮汹涌 近期，Lancet. 发表了一项基于2021年全球疾病负担、伤害及风险因素研究（GBD）的最新成果，利用相关数据更新了1990至2021年间204个 国家和地区按年龄及性别划分的成人超重和肥胖患病率估算 ...

Core Viewpoint - A groundbreaking study from Chinese scientists has demonstrated the potential for curing type 1 diabetes through stem cell technology, marking a significant advancement in the treatment of this chronic condition [4][5][7]. Group 1: Breakthrough in Type 1 Diabetes Treatment - The study published in *Cell* details the world's first successful case of a patient with type 1 diabetes being able to stop insulin use after receiving a transplant of chemically induced pluripotent stem cell-derived islets (CiPSC) [5][7]. - The patient, a 25-year-old male with a history of liver complications and previous unsuccessful pancreas transplant, achieved stable blood sugar levels within 75 days post-transplant, with HbA1c dropping to 5% and time in range (TIR) exceeding 98% [6][7]. - This case not only validates the safety and efficacy of CiPSC transplantation but also offers a new clinical pathway for potentially curing type 1 diabetes, which has traditionally been viewed as a lifelong condition requiring insulin [7][8]. Group 2: Innovative Techniques and Future Implications - The treatment utilizes chemical reprogramming to convert the patient's own pluripotent stem cells into functional insulin-producing cells, overcoming previous limitations related to cell sourcing [8]. - The innovative choice of the abdominal anterior rectus sheath as the transplant site has shown promising results, indicating a significant advancement in the methodology of diabetes treatment [8]. - The medical community views this achievement as a pivotal moment in regenerative medicine for metabolic diseases, with the potential to reshape diabetes treatment paradigms if further large-scale clinical trials confirm these results [8].

Core Insights - Eli Lilly is projected to become the highest-selling biopharmaceutical company globally by 2030, with sales expected to reach $113 billion, significantly surpassing Novo Nordisk's anticipated $84 billion [2] - The diabetes and obesity drug market is expected to dominate, with an average annual growth rate of 20% from 2024 to 2030 [2] - GLP-1 receptor agonists and related drugs are expected to account for nearly 9% of the global prescription drug market by 2030, marking a significant category in the pharmaceutical landscape [2] Group 1: Sales Projections - Eli Lilly's diabetes treatment Mounjaro is expected to become the best-selling drug globally by 2030, with projected sales of $36 billion [4] - Novo Nordisk's drugs, including Ozempic and Wegovy, are also expected to rank among the top ten best-selling drugs, with sales of $24.4 billion and $18.1 billion respectively [4] - Three clinical-stage obesity drugs are anticipated to enter the global sales top ten by 2030, with Eli Lilly's Orforglipron and Retatrutide projected to achieve sales of $12.7 billion and $5.6 billion respectively [4] Group 2: Company Rankings and Growth - The top seven companies in global prescription drug sales for 2024 are projected to be Johnson & Johnson, AbbVie, Merck, Roche, Pfizer, AstraZeneca, and Novartis, with sales ranging from $50.2 billion to $55.7 billion [5] - Eli Lilly and Novo Nordisk are expected to surpass these companies by 2030, with AbbVie showing significant growth to $75.3 billion, driven by its immunology drugs [5][6] - Sanofi is projected to grow from $44.2 billion in 2024 to $64.8 billion by 2030, largely due to its drug Dupixent [6] Group 3: Market Dynamics - Roche is expected to see its overall prescription drug sales increase from $52.5 billion to $66.3 billion by 2030, despite not having any single drug in the top ten [7] - Merck's sales are projected to grow from $54.3 billion to $60 billion, with Keytruda facing competition from biosimilars [7] - The rapid expansion of the diabetes and obesity treatment market is reshaping the pharmaceutical industry, positioning Eli Lilly and Novo Nordisk as new leaders [8]

Core Viewpoint - Weight loss is often confused with fat loss, but they are fundamentally different. Weight loss refers to the overall decrease in body weight, including fat, muscle, and water, while fat loss focuses specifically on reducing fat content and lowering body fat percentage, which is a more scientific and healthier approach to weight management [2][4]. Group 1: Understanding Body Composition - Body composition can be divided into "lean body mass" and "total fat mass." Standard scales only show total weight changes and do not reflect fat loss. Generally, male body fat percentage should be maintained between 15%-18%, while for females, it should be between 25%-28% [4]. - For individuals with a higher initial weight, the priority should be weight loss, while those with a lower initial weight should focus on fat loss [4]. Group 2: Scientific Weight Loss Strategies - Effective fat loss requires a comprehensive lifestyle intervention, including a balanced diet, appropriate exercise, sufficient sleep, and a positive mindset. The "20 Guidelines for Weight Management" from the Chinese residents' health initiative emphasizes the importance of lifestyle changes [4]. - The "2024 Adult Obesity Dietary Guidelines" from the National Health Commission provides detailed dietary guidance, highlighting the importance of controlling total energy intake and optimizing dietary structure [4]. Group 3: Dietary Recommendations - Avoiding extreme dieting is crucial, as it may lead to muscle loss rather than fat loss. Muscle is essential for maintaining metabolic rate, and its reduction can hinder fat metabolism [6]. - The recommended daily caloric intake for men is between 1750-1950 kcal, but should not fall below 1200 kcal. A "small meals frequently" approach is suggested to prevent binge eating due to hunger [6]. - A balanced diet should primarily consist of grains, vegetables, fruits, and lean proteins while reducing oil, salt, and sugar intake. The Mediterranean diet is highlighted as beneficial for health and weight management [8][10]. Group 4: Specific Dietary Patterns - The Jiangnan diet, representative of the health dietary pattern in China, emphasizes a variety of ingredients, high vegetable and fruit intake, and lower consumption of red meat, which may help control weight and reduce chronic disease risk [10]. - Dairy products are recommended for their high-quality protein and calcium content, with a daily intake of 300-500g of liquid milk or equivalent dairy products suggested [11]. Group 5: Short-term Weight Loss Techniques - Adjusting the macronutrient ratio (low carb, low fat, high protein) can lead to short-term weight loss, but long-term effects are not well-supported. Intermittent fasting shows some weight loss benefits but lacks long-term evidence [12][14]. - The ketogenic diet, characterized by very low carbohydrate intake, can improve weight management but should be followed under professional guidance due to safety concerns [13]. Group 6: Behavioral Changes - Eating speed is linked to obesity, and reducing eating speed can help with weight loss by decreasing caloric intake and increasing satiety hormones. It is recommended that adults take more than 20 minutes per meal [15]. - Skipping breakfast and late-night eating are associated with increased obesity risk. Eating breakfast helps maintain stable blood sugar levels and reduces hunger later in the day [14]. Group 7: GLP-1 Medications - The approval of semaglutide (Nuoheying) for long-term weight management in China marks a significant development. This GLP-1 receptor agonist can achieve an average weight reduction of 17% (approximately 16.8 kg) and offers multiple health benefits beyond weight loss [17][18].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 三月不减肥，五月徒伤悲。没想到，今年的减肥热潮来得如此猛烈，甚至2025年最"卷"的KPI，竟然成了体重管理！在第十四届全国人大三次 会议上，国家卫健委专门用了7分钟强调体重管理的重要性。网友们纷纷调侃"国家喊你减肥"、"国家不让你胖"，体重管理相关话题连续多天霸 占热搜榜。当然，这可不是一句口号，国家卫健委已经正式启动【体重管理三年计划】，推出了【体重管理门诊】和【科学食谱指南】，为大 家科学减重保驾护航。那么，国家为何如此关注我们的卡路里？今天就带大家一起揭秘背后的真相。 《柳叶刀》最新研究显示，截至2021年，中国25岁及以上超重和肥胖人数已达4.02亿，位居全球首位。根据卫健委发布的《体重管理指导原则 （2024年版）》，有专家预测，如果不及时遏制，2030年我国成人超重肥胖率将飙升至70.5%，儿童超重肥胖率也将达到31.8%。这意味着： 每3个成年人中就有2个体重超标，每3个孩子中就有1个可能被肥胖困扰。 国家出台多项举措鼓励大家科学减重， ...

Core Insights - The article discusses a groundbreaking study published in "Nature Medicine" that reveals the significant role of gut microbiota in the development and management of type 2 diabetes (T2DM) through metabolic reprogramming [3][4][8]. Group 1: Research Findings - The study integrates multi-omics analysis to elucidate the molecular mechanisms by which gut microbiota influences glucose metabolism, highlighting the interaction between gut microbiota and blood metabolites [3][6][11]. - It identifies 502 metabolites significantly associated with glucose metabolism abnormalities, with a notable contribution of gut microbiota accounting for nearly 30% of blood metabolite variation [8][9]. - Specific microbial species were linked to key metabolites, indicating their potential as intervention targets for diabetes management [9][11]. Group 2: Clinical Implications - The research suggests a paradigm shift in diabetes treatment from mere pharmacological control to metabolic restoration through personalized dietary interventions and gut microbiota modulation [4][10]. - Clinical trials showed that 65% of participants achieved normalized glucose metabolism indicators after 12 months of personalized dietary intervention, closely related to gut microbiota reprogramming [3][4]. - The findings emphasize the importance of early intervention and personalized strategies in diabetes prevention and management, potentially reducing the risk of complications [4][12]. Group 3: Methodology and Validation - The study utilized a dual-cohort design with high-throughput metabolomics to analyze 978 plasma metabolites and identified 1,427 microbial gene clusters [6][7]. - Machine learning algorithms were employed to establish predictive models for metabolite levels based on clinical indicators, dietary intake, and microbiota characteristics, enhancing the reliability of the findings [7][8]. - An interactive network platform was developed to facilitate global research collaboration and data analysis, promoting the advancement of personalized diabetes intervention strategies [7][10].

整理 | GLP1减重宝典内容团队 礼来加拿大公司（Eli Lilly Canada）宣布，ZEPBOUND™ KwikPen®（替尔泊肽注射液）现已在加拿大正式上市。这款每周一次的注 射剂，为患有肥胖或超重的成年患者提供了新的慢性体重管理方案。该药物已获得加拿大卫生部批准，用于与健康饮食和规律运动相结 合的长期体重控制。 激活双重激素受体的新机制 ZEPBOUND™通过同时激活两种激素受体——GIP（葡萄糖依赖性促胰岛素多肽）和GLP-1（胰高血糖素样肽-1）——来调节食欲和代 谢。这是加拿大首个也是唯一一个被批准用于长期体重管理的双受体激动剂，具有减重和维持体重的双重作用。 ZEPBOUND™适用于体重指数（BMI）为30及以上的成人，或BMI在27至30之间但患有与体重相关疾病的患者，例如高血压、血脂异 常、2型糖尿病、睡眠呼吸暂停症或心血管疾病。 应对日益严峻的健康挑战 "肥胖是一种严重的慢性疾病，对健康有广泛影响。"礼来加拿大公司总经理兼总裁Mathilde Merlet表示，"如果不加干预，它会引发多 种慢性病，增加医疗系统负担，降低劳动生产率，甚至导致残疾。ZEPBOUND™的推出，是我们在肥胖 ...